These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29928211)

  • 1. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.
    Hirakawa H; Komiya K; Nakashima C; Ogusu S; Nakamura T; Tanaka M; Takahashi K; Egashira Y; Kai K; Kimura S; Sueoka-Aragane N
    Ann Transl Med; 2018 Dec; 6(23):464. PubMed ID: 30603652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
    Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
    Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Nishimatsu K; Minami S; Ihara S; Yasuoka H
    J Med Cases; 2021 Aug; 12(8):310-314. PubMed ID: 34434479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
    Nishioka N; Yamada T; Harita S; Hirai S; Katayama Y; Nakano T; Okura N; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Respir Med Case Rep; 2018; 25():261-263. PubMed ID: 30310765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
    Liu J; Xia L; Peng Y; Huang YS; Yang ZZ
    Medicine (Baltimore); 2021 Oct; 100(39):e27289. PubMed ID: 34596125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
    BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
    Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
    Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.
    Li J; Liu X; Yuan C
    Mol Clin Oncol; 2018 Sep; 9(3):321-324. PubMed ID: 30112177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report.
    Moriguchi S; Uruga H; Fujii T; Yasunaga Y; Takahashi Y; Kishi K
    Respirol Case Rep; 2019 Apr; 7(3):e00402. PubMed ID: 30828454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review.
    Leonetti A; Minari R; Mazzaschi G; Gnetti L; La Monica S; Alfieri R; Campanini N; Verzè M; Olivani A; Ventura L; Tiseo M
    Front Oncol; 2021; 11():642190. PubMed ID: 33981604
    [No Abstract]   [Full Text] [Related]  

  • 19. Squamous cell transformation and
    Bruno R; Proietti A; Alì G; Puppo G; Ribechini A; Chella A; Fontanini G
    Oncol Lett; 2017 Nov; 14(5):5947-5951. PubMed ID: 29113230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.